Lorem ipsum dolor amet elit dolor es (h1)
Maecenas fermentum, risus vitae malesuada euismod, urna arcu sodales leo, ac dapibus nisl purus porttitor quam
Nunc mattis in est ut
suscip quam (h2)
Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse porttitor, augue egestas aliquam porta, lacus turpis dignissim felis, at egestas lectus tellus a libero.
Duis mattis nisi risus. Integer pulvinar id odio gravida sagittis. Suspendisse maximus mi sit amet libero porttitor pellentesque ac et massa. Mauris elementum finibus accumsan. Nunc mattis in est ut suscipit. Vivamus ullamcorper augue arcu, non condimentum mauris finibus ac. Vestibulum sed facilisis nisi, sed pretium quam.
Nunc mattis in est ut
suscip quam (h2)
Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse porttitor, augue egestas aliquam porta, lacus turpis dignissim felis, at egestas lectus tellus a libero.
Duis mattis nisi risus. Integer pulvinar id odio gravida sagittis. Suspendisse maximus mi sit amet libero porttitor pellentesque ac et massa. Mauris elementum finibus accumsan. Nunc mattis in est ut suscipit. Vivamus ullamcorper augue arcu, non condimentum mauris finibus ac. Vestibulum sed facilisis nisi, sed pretium quam.
Contact form
LOREM IPSUM DOLOR ES
How do life sciences leaders
leverage our technology (h2)
Our solutions combine mobile and web technology, leveraging our proven Theraxium platform, with embedded evidence-based clinical algorithms to adjust treatment dosage, support adherence to treatment and manage symptoms related to the treatment and the disease. Our mission is to help deliver a better care by optimizing the real-world use of medication and, ultimately, improve real-world outcomes.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus interdum, neque leo iaculis velit, sed finibus quam nulla id felis. Nulla eu rutrum dolor. Aenean est justo, egestas ac pellentesque facilisis, tincidunt sit amet diam.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus interdum, neque leo iaculis velit, sed finibus quam nulla id felis. Nulla eu rutrum dolor. Aenean est justo!
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur magna augue, vehicula et imperdiet rhoncus, rutrum eu ipsum. Sed ultricies, enim sit amet maximus
Nunc mattis in est ut
suscip quam (h3)
Nunc mattis in est ut suscip quam (h4)
- On the commercial side, Voluntis is aiming to sign new cooperation agreements in 2021.
- On the financial side, based on its current available information, the company confirms its annual commercial invoicing objective of between € 8 and 12 million, and still targets a positive free cash flow in the second half of the year.
- On the financial side, based on its current available information, the company confirms
- On the financial side, based on its current available information
Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse porttitor, augue egestas aliquam porta, lacus turpis dignissim felis, at egestas lectus tellus a libero.
Duis mattis nisi risus. Integer pulvinar id odio gravida sagittis. Suspendisse maximus mi sit amet libero porttitor pellentesque ac et massa. Mauris elementum finibus accumsan. Nunc mattis in est ut suscipit. Vivamus ullamcorper augue arcu, non condimentum mauris finibus ac. Vestibulum sed facilisis nisi, sed pretium quam.
How do life sciences leaders
leverage our technology (h2)
title h5
Our solutions combine mobile and web technology, leveraging our proven Theraxium platform, with embedded evidence-based clinical algorithms to adjust treatment dosage!
This is a quote year after the presentation of our new strategic roadmap, I am very proud of the progress we have made. We are on track on all key indicators, whether it is the conclusion of agreements, with new milestone partnerships with two leading pharmaceutical companies, the improvement of our results, thanks to the optimization of our cost structure, or our financial visibility with a growing cash flow. »
Pierre Leurent, CEO of Voluntis
Toggle content
Focus on patients that requires attention:
- Extend their support to patients through a digital device they prescribe.
- Intervene at the right time with the right data.
- Leverage tools that promote evidence-based treatment management and supportive care strategies.
Life sciences companies
Toggle content
High patient engagement
At Voluntis, we share the vision that empowering patients to self-manage their treatment can improve
of patients contine with Insulia
AFTER 1 MONTH
of active patients interact with Insulia every day
AFTER 1 MONTH
At Voluntis, we share the vision that empowering patients:
LOREM IPSUM
of active patients acept Insulia’s recommanded dose
LOREM IPSUM
of active patients acept Insulia’s recommanded dose
Tables
We are on a mission to deliver this vision through digitally-augmented therapies to put patients back in control of their disease. We believe that patients’ experience with their treatment can be improved by putting the right tool in their hands to:
Table standard width
2019 | 2020 | |
Sales invoicing | 2.7 | 10.2 |
Adjusted EBITDA | (13.4) | (3.4) |
Operating income | (13.4) | (3.4) |
Cash and cash equivalents net of financial debts | (2.5) | 2.9 |
Table large width
2019 | 2020 | 2021 | 2022 | |
Sales invoicing | 2.7 | 10.2 | 2.7 | 10.2 |
Cash and cash equivalents net of financial debts | 2.7 | 10.2 | 2.7 | 10.2 |
Adjusted EBITDA | 2.7 | 10.2 | 2.7 | 10.2 |
Sales invoicing | 2.7 | 10.2 | 2.7 | 10.2 |
How do life sciences leaders
leverage our technology (h2)
Our solutions combine mobile and web technology, leveraging our proven Theraxium platform, with embedded evidence-based clinical algorithms to adjust treatment dosage, su
Our culture
Our people
Lisa Kiblinger
Senior Manager, Medical Affairs Diabetes
Frédéric Tan
Project Manager Diabetes
Mireille Mazloum
Services & Solution Design Manager
Lorem ipsum title h2
Lorem ipsum title h3
Lorem ipsum title h4
Lorem ipsum title h5
Lorem ipsum title h6
Our solutions combine mobile and web technology, leveraging our proven Theraxium platform, with embedded evidence-based clinical algorithms to adjust treatment dosage
- Our solutions combine mobile and web technology,
- leveraging our proven Theraxium platform,
- with embedded evidence-based clinical algorithms to adjust treatment dosage
€m | 2019 | 2020 | |
Sales invoicing | 2.7 | 10.2 | |
Revenues | 3.7 | 4.4 | |
Adjusted EBITDA | (13.4) | (3.4) | |
EBITDA | (12.5) | (9.1) | |
Operating income | (14.8) | (11.1) | |
Free cash flow | (14.3) | (2.1) |
Contact presse
Title – vol events
Label
Lorem ipsum
-
titre text
Engineering
With over 40 solutions built and a versatile and modular platform for DTx, the Voluntis team has developed a unique expertise in developing software medical devices.
Solutions Design
We create digital therapeutics in line with the IEC 62366 for usability and human factors engineering of medical devices.